Hofmockel G, Theiss M, Bussen D, Wirth M P, Frohmüller H G
Urologische Klinik und Poliklinik der Universität Würzburg.
Urologe A. 1994 Sep;33(5):434-9.
Twenty-three patients with advanced renal cell carcinoma were treated with subcutaneous injections of interleukin-2 (IL-2) and interferon-alpha (IFN-alpha). IFN-alpha (5-10(6) U/m2) was injected on day 1 of the 1st week of a treatment cycle of 6 weeks and high doses of IL-2 (20.10(6) IU/m2) on days 3, 4 and 5. In the 2nd and 3rd week IFN-alpha (dose as above) and low doses of IL-2 (5.10(6) IU/m2) were injected on days 1, 3 and 5. The treatment from the 4th to the 6th week corresponded to that of the 1st to 3rd week. In cases of remission or stable disease the treatment schedule was repeated as a rule once or twice. In 12 of the 23 cases nephrectomy had been carried out previously. Complete remission lasting 4 + months and partial remission lasting 2 months were achieved in two patients with lung and skeletal metastases. A stable state of the disease lasting 1-7 + months was observed in 11 cases. Ten patients showed progression of the disease after the first treatment cycle. Thus, the overall objective response rate was 9%. The side effects were only slight and corresponded to WHO toxicity grade I (n = 8) and grade II (n = 15). In two cases the first treatment cycle could not be finished.
23例晚期肾细胞癌患者接受了皮下注射白细胞介素-2（IL-2）和α干扰素（IFN-α）的治疗。在为期6周的治疗周期的第1周第1天注射IFN-α（5-10⁶ U/m²），在第3、4和5天注射高剂量的IL-2（20×10⁶ IU/m²）。在第2和3周，于第1、3和5天注射IFN-α（剂量同上）和低剂量的IL-2（5×10⁶ IU/m²）。第4至6周的治疗与第1至3周相同。在缓解或病情稳定的情况下，治疗方案通常重复一到两次。23例患者中有12例先前已行肾切除术。两名有肺和骨转移的患者分别实现了持续4个多月的完全缓解和持续2个月的部分缓解。11例患者病情稳定达1至7个多月。10例患者在第一个治疗周期后病情进展。因此，总体客观缓解率为9%。副作用轻微，符合世界卫生组织毒性分级I级（n = 8）和II级（n = 15）。2例患者无法完成第一个治疗周期。
